

- *NRC's Agencywide Documents Access and Management System (ADAMS)*: You may obtain publicly available documents online in the ADAMS Public Documents collection at <https://www.nrc.gov/reading-rm/adams.html>. To begin the search, select "Begin Web-based ADAMS Search." For problems with ADAMS, please contact the NRC's Public Document Room (PDR) reference staff at 1-800-397-4209, 301-415-4737, or by email to PDR.Resource@nrc.gov. For the convenience of the reader, instructions about obtaining materials referenced in this document are provided in the "Availability of Documents" section.

- *NRC's PDR*: You may examine and purchase copies of public documents, by appointment, at the NRC's PDR, Room P1 B35, One White Flint North, 11555 Rockville Pike, Rockville, Maryland 20852. To make an appointment to visit the PDR, please send an email to PDR.Resource@nrc.gov or call 1-800-397-4209 or 301-415-4737, between 8:00 a.m. and 4:00 p.m. (ET), Monday through Friday, except Federal holidays.

FOR FURTHER INFORMATION CONTACT:
George Alexander, Office of Nuclear

Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001; telephone: 301-415-6755; email: George.Alexander@nrc.gov.

SUPPLEMENTARY INFORMATION:

I. Background

The Sigma-Aldrich Company's (Sigma's) Fort Mims Site is located at 11542 Fort Mims Drive, Maryland Heights, Missouri in a commercial/industrial park. The site consists of a 3-acre parcel of land previously used for the radiolabeling of chemicals with carbon-14 and tritium.

II. Discussion

By email dated August 22, 2019, the NRC received an application to amend Sigma's decommissioning plan. That application was supplemented by letter dated April 27, 2020, requesting a license amendment for the termination of NRC Materials License No. 24-16273-01, and by letter dated October 19, 2020, providing the NRC Form 313 "Application for Materials License" for this action. By email dated July 31, 2020, the NRC staff accepted for detailed technical review Sigma's license amendment request to amend

the decommissioning plan and terminate the license.

The NRC staff reviewed the revised decommissioning plan with the site-specific dose model and license termination request. Based on Sigma's dose analysis and the NRC's independent and confirmatory surveys and analyses, the NRC staff concluded in a safety evaluation report dated November 16, 2021, that the Fort Mims Site met the dose criteria for unrestricted use and that the residual radioactivity is as low as reasonably achievable, consistent with section 20.1402 of title 10 of the *Code of Federal Regulations*, "Radiological criteria for unrestricted use." Based on an environmental assessment dated November 12, 2021, NRC staff concluded that there would be no significant environmental impacts. Accordingly, NRC Materials License No. 24-16273-01 for the Fort Mims Site was terminated.

III. Availability of Documents

The documents identified in the following table are available to interested persons through ADAMS, as indicated.

Document	ADAMS accession No.
NRC Approval of Sigma-Aldrich Company's Fort Mims Facility Decommissioning Plan, dated May 12, 2009	ML091330309
Sigma-Aldrich Fort Mims Site Revised Decommissioning Plan, dated June 27, 2019	ML19273A160
Transmittal Email—Sigma-Aldrich Fort Mims Revised Decommissioning Plan, dated August 22, 2019	ML19273A163
Sigma-Aldrich Fort Mims Site Request for License Termination, dated April 27, 2020	ML20120A544
Transmittal Email—NRC Acceptance Review of Revised Decommissioning Plan and License Termination Request, dated July 31, 2020.	ML20213C693
Sigma-Aldrich Fort Mims Site Revised Decommissioning Plan: NRC Form 313, "Application for Materials License," dated October 19, 2020.	ML20294A191
NRC Environmental Assessment and Finding of No Significant Impact Related to the Issuance of a License Amendment for the Sigma-Aldrich Fort Mims Site, dated November 12, 2021.	ML21277A097
NRC Safety Evaluation Report of Revised Decommissioning Plan and License Termination Request for the Sigma-Aldrich Fort Mims Site, dated November 16, 2021.	ML21300A384
NRC Materials License 24-16273-01 Termination Amendment 21, dated November 16, 2021	ML21300A383

Dated: January 25, 2022.

For the Nuclear Regulatory Commission.

Randolph W. Von Till,

Chief, Uranium Recovery and Materials Decommissioning Branch, Division of Decommissioning, Uranium Recovery and Waste Programs, Office of Nuclear Material Safety and Safeguards.

[FR Doc. 2022-01754 Filed 1-27-22; 8:45 am]

BILLING CODE 7590-01-P

NUCLEAR REGULATORY COMMISSION

[NRC-2022-0001]

Sunshine Act Meetings

TIME AND DATE: Weeks of January 31, February 7, 14, 21, 28, March 7, 2022.

PLACE: Commissioners' Conference Room, 11555 Rockville Pike, Rockville, Maryland.

STATUS: Public.

Week of January 31, 2022

There are no meetings scheduled for the week of January 31, 2022.

Week of February 7, 2022—Tentative

Tuesday, February 8, 2022

10:00 a.m. Meeting with the Organization of Agreement States and the Conference of Radiation Control Program Directors (Public Meeting); (Contact: Celimar Valentin-Rodriguez: 301-415-7124).

Additional Information: The public is invited to attend the Commission's meeting live by webcast at the Web address—<https://video.nrc.gov/>. For those who would like to attend in person, note that all visitors are required to complete the NRC Self-Health Assessment and Certification of Vaccination forms. Visitors who certify

that they are not fully vaccinated or decline to complete the certification must have proof of a negative Food and Drug Administration-approved polymerase chain reaction (PCR) or Antigen (including rapid tests) COVID-19 test specimen collection from no later than the previous 3 days prior to entry to an NRC facility. The forms and additional information can be found here <https://www.nrc.gov/about-nrc/covid-19/guidance-for-visitors-to-nrc-facilities.pdf>.

Week of February 14, 2022—Tentative

There are no meetings scheduled for the week of February 14, 2022.

Week of February 21, 2022—Tentative

Thursday, February 24, 2022

10:00 a.m. Briefing on Regulatory Research Program Activities (Public Meeting); (Contact: Nick Difrancesco: 301-415-1115).

Additional Information: The public is invited to attend the Commission's meeting live by webcast at the Web address—<https://video.nrc.gov/>. For those who would like to attend in person, note that all visitors are required to complete the NRC Self-Health Assessment and Certification of Vaccination forms. Visitors who certify that they are not fully vaccinated or decline to complete the certification must have proof of a negative Food and Drug Administration-approved polymerase chain reaction (PCR) or Antigen (including rapid tests) COVID-19 test specimen collection from no later than the previous 3 days prior to entry to an NRC facility. The forms and additional information can be found here <https://www.nrc.gov/about-nrc/covid-19/guidance-for-visitors-to-nrc-facilities.pdf>.

Week of February 28, 2022—Tentative

There are no meetings scheduled for the week of February 28, 2022.

Week of March 7, 2022—Tentative

There are no meetings scheduled for the week of March 7, 2022.

CONTACT PERSON FOR MORE INFORMATION: For more information or to verify the status of meetings, contact Wesley Held at 301-287-3591 or via email at Wesley.Held@nrc.gov. The schedule for Commission meetings is subject to change on short notice.

The NRC Commission Meeting Schedule can be found on the internet at: <https://www.nrc.gov/public-involve/public-meetings/schedule.html>.

The NRC provides reasonable accommodation to individuals with disabilities where appropriate. If you

need a reasonable accommodation to participate in these public meetings or need this meeting notice or the transcript or other information from the public meetings in another format (e.g., braille, large print), please notify Anne Silk, NRC Disability Program Specialist, at 301-287-0745, by videophone at 240-428-3217, or by email at Anne.Silk@nrc.gov. Determinations on requests for reasonable accommodation will be made on a case-by-case basis.

Members of the public may request to receive this information electronically. If you would like to be added to the distribution, please contact the Nuclear Regulatory Commission, Office of the Secretary, Washington, DC 20555, at 301-415-1969, or by email at Tyesha.Bush@nrc.gov or Betty.Thweatt@nrc.gov.

The NRC is holding the meetings under the authority of the Government in the Sunshine Act, 5 U.S.C. 552b.

Dated: January 26, 2022.

For the Nuclear Regulatory Commission.

Wesley W. Held,

Policy Coordinator, Office of the Secretary.

[FR Doc. 2022-01953 Filed 1-26-22; 4:15 pm]

BILLING CODE 7590-01-P

PENSION BENEFIT GUARANTY CORPORATION

Proposed Submission of Information Collection for OMB Review; Comment Request; Medical Exception Request

AGENCY: Pension Benefit Guaranty Corporation.

ACTION: Notice of intent to request extension of OMB approval of information collection.

SUMMARY: The Pension Benefit Guaranty Corporation (PBGC) intends to request that the Office of Management and Budget (OMB) extend approval, without change, under the Paperwork Reduction Act, of a collection of information for its employees to request a medical exception to the COVID-19 vaccination requirement.

DATES: Comments must be submitted on or before March 29, 2022.

ADDRESSES: Comments may be submitted by any of the following methods:

- *Federal eRulemaking Portal:* <http://www.regulations.gov>. Follow the instructions for submitting comments.
- *Email:* paperwork.comments@pbgc.gov. Refer to OMB control number 1212-0075 in the subject line.
- *Mail or Hand Delivery:* Regulatory Affairs Division, Office of the General Counsel, Pension Benefit Guaranty

Corporation, 1200 K Street NW, Washington, DC 20005-4026.

Commenters are strongly encouraged to submit public comments electronically. PBGC expects to have limited personnel available to process public comments that are submitted on paper through mail. Until further notice, any comments submitted on paper will be considered to the extent practicable.

All submissions received must include the agency's name (Pension Benefit Guaranty Corporation, or PBGC) and refer to OMB control number 1212-0075. All comments received will be posted without change to PBGC's website, <http://www.pbgc.gov>, including any personal information provided. Commenters should not include any information for which disclosure is restricted by statute, such as trade secrets and commercial or financial information ("confidential business information"). Submission of confidential business information without a request for protected treatment constitutes a waiver of any claims of confidentiality.

Copies of the collection of information may be obtained by writing to Disclosure Division, Office of the General Counsel, Pension Benefit Guaranty Corporation, 1200 K Street NW, Washington, DC 20005-4026, or calling 202-229-4040 during normal business hours. TTY users may call the Federal Relay Service toll-free at 800-877-8339 and ask to be connected to 202-229-4040.

FOR FURTHER INFORMATION CONTACT:

Melissa Rifkin (rifkin.melissa@pbgc.gov), Attorney, Regulatory Affairs Division, Office of the General Counsel, Pension Benefit Guaranty Corporation, 1200 K Street NW, Washington, DC 20005-4026; 202-229-6563. (TTY and TDD users may call the Federal relay service toll-free at 800-877-8339 and ask to be connected to 202-229-6563.)

SUPPLEMENTARY INFORMATION: Under Executive Order 14043, every Federal agency must "implement, to the extent consistent with applicable law, a program to require COVID-19 vaccination for all of its Federal employees, with exceptions only as required by law." In following this directive, the Pension Benefit Guaranty Corporation (PBGC) has a requirement that its employees must receive and submit proof of a COVID-19 vaccination. As required by 29 U.S.C. 701 *et seq.* and 29 CFR part 1630, PBGC allows an exception from the vaccination requirement for employees who demonstrate medical reasons or disabilities that would make the COVID-19 vaccine unsafe for them. To